Loading patent…
AssigneeCell2In, Inc.
InventorsHeun Soo KANG, Hye Mi KIM, Ji Eun SONG, Yingfu YIN, Ji Woong SHIN, Hye Won KANG, Yong Hwan KIM
Estimating the term…
The present invention relates to a therapeutic stem cell composition comprising a stem cell in which the expression level of any one or more genes selected from the group consisting of ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-Actin, Mlc2v and Runx1 is higher or lower than the expression level of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.
1-90. (canceled)
A therapeutic stem cell in which the expression level of any one or more selected from the group consisting of OCT4, SOX2, cMET, PDGFRA, PDGFRB, VEGF-R1 and VEGF-R2 is higher or lower than the expression level of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.
Dependencies are inferred from the claim text.